Alkermes Comments On FDA Panel May Pressure Shares, Says Mizuho
August 21, 2020 at 12:16 PM EDT
Analyst Vamil Divan believes details in Alkermes' announcement this morning that the FDA will hold an advisory committee meeting on October 9 to discuss ALKS 3831, a treatment of schizophrenia and bipolar disorder, may put pressure on the shares.
